Clinical Trial Update: Traumastem® Versus Surgicel® for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Traumastem® to Surgicel® for secondary treatment of local bleeding in hepatic resection completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Hemorrhage

Drugs mentioned

• Surgicel (oxidized regenerated cellulose)
• Traumastem®

Snippet

Sponsor: China Medical University, China | Conditions: Liver Hemorrhage | Phase 3 | Status: COMPLETED